Time to focus on the locus

Archives of Neurology

Volumn 60, Issue 3, 2003, Pages 320-

  Rye, David ^b   DeLong, Mahlon R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; BRAIN SCINTIANGIOGRAPHY; BRAIN TISSUE; CELL LOSS; CHOLINERGIC NERVE CELL; CORRELATION ANALYSIS; CYTOPATHOLOGY; EDITORIAL; HUMAN; LOCUS CERULEUS; NERVE CELL DEGENERATION; NEUROCHEMISTRY; NEUROPATHOLOGY; NORADRENERGIC NERVE; PARKINSON DISEASE; PRIORITY JOURNAL;

ALZHEIMER DISEASE; HUMANS; LOCUS COERULEUS; PARKINSON DISEASE;

EID: 0037338543     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.60.3.320     Document Type: Editorial

References (7)

1. Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol. 2003;60:337-341.
2. Jellinger K. Pathology of Parkinson's disease: changes other than the nigrostriatal pathway. Mol Chem Neuropathol. 1991;14:153-197.
3. Trojanowski J. Tauists, Baptists, Syners, Apostates and new data. Ann Neurol. 2002;52:263-265.
4. Bing G, Zhang Y, Watanabe Y, McEwen B, Stone E. Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra. Brain Res. 1994;668:261-265.
5. Mavridis M, Degryse A-D, Lategan AJ, Marien MR, Colpaert FC. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys. Neuroscience. 1991;41:507-523.
6. Freeman A, Ciliax B, Bakay R, et al. Nigrostriatal collaterals to thalamus degenerate in parkinsonian animal models. Ann Neurol. 2001;50:321-329.
7. Henderson J, Carpenter K, Cartwright H, Halliday G. Degeneration of the centre median-parafascicular complex in Parkinson's disease. Ann Neurol. 2000;47:345-352.